作为PD-1/PD-L1相互作用的光激活的阿佐烯抑制剂
Deanne Hayward1, Zoë R Goddard1, Marco M D Cominetti1
1School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR47TJ, UK. A.Beekman@uea.ac.uk.
概括
研究人员创造了一种新型的光控制来抑制PD-1/PD-L1相互作用,为抗体提供一种潜在的更容易获得的癌症免疫疗法替代品.
科学领域:
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- PD-1/PD-L1通路是癌症免疫治疗的关键目标.
- 目前基于抗体的疗法面临的局限性包括高成本,副作用和有限的应用.
研究的目的:
- 开发一种新型的,光控制的,PD-1/PD-L1相互作用的抑制剂.
- 探索一种潜在的更具成本效益和选择性的替代抗体疗法.
主要方法:
- 设计和合成一个光控制的阿佐烯.
- 使用体外试验测试评估活性.
- 在相关测定中评估细胞活动.
主要成果:
- 开发出来的亚博烯可以选择性地抑制PD-1/PD-L1相互作用.
- 抑制是异构体特定的,只发生在 cis 同构体上.
- 通过体外和细胞测定证实了活性.
结论:
- 照相控制的代表了癌症免疫治疗的有希望的新模式.
- 这种方法在选择性和成本方面比现有的抗体治疗方法具有潜在的优势.
相关概念视频
Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...


